MedPath

Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions (DEXA-REFINE)

Phase 4
Not yet recruiting
Conditions
Acute Hypoxemic Respiratory Failure
Registration Number
2024-519759-27-00
Lead Sponsor
Consorcio Centro De Investigacion Biomedica En Red
Brief Summary

The effects 20/10 mg vs. 6 mg of intravenous dexamethasone on the number of deaths at 60 days after randomization and the number of days alive without ventilator support at 28 days, and other subjectcentered outcomes in adult subjects with AHRF (including ARDS) caused by pulmonary or systemic infections (including COVID-19). Death from any cause 60 days after randomization. Death, if occurred, will be recorded irrespective whether the subject remains in the same hospital, in another health care facility, or discharged home. If subjects are discharged alive from hospital before day 60, clinical status information at 60 days will be obtained from the electronic clinical record.

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised, recruitment pending
Sex
Not specified
Target Recruitment
980
Inclusion Criteria

Age ≥18 years.

Intubated and mechanically ventilated, defined as requiring ventilatory support at the time of Screening.

Acute onset of AHRF (as defined by a PaO2/FiO2 ≤300 mmHg during at least 6 hours from diagnosis. For the measurement of PaO2 and calculation of PaO2/FiO2 ratio, the minimum accepted value for PEEP is 5 cmH2O and for FiO2 is 0.3. ARDS is defined by Berlin criteria,4 which includes: (i) having pneumonia or worsening respiratory symptoms, (ii) bilateral pulmonary infiltrates on chest imaging (x-ray or CT scan), (iii) absence of left atrial hypertension or no clinical signs of left heart failure, and (iv) hypoxemia, as defined by a PaO2/FiO2 ≤300 mmHg on positive end-expiratory pressure (PEEP) of ≥5 cmH2O, regardless of FiO2.

Pulmonary or systemic infectious etiology of AHRF.

Exclusion Criteria

Subjects with a known contraindication to corticosteroids or know hypersensitivity. History of any hypersensitivity reaction to dexamethasone, including but not limited to urticaria, eczema, angioedema, bronchospasm, and anaphylaxis.

Subjects who have an indication of chronic use of higher doses of systemic corticosteroids. Use of systemic corticosteroids in doses higher than 6 mg dexamethasone equivalents for other indications than COVID- 19: systemic corticosteroids in doses higher than 6 mg dexamethasone / 6 mg betamethasone / 200 mg cortisone / 160 mg hydrocortisone / 32 mg methylprednisolone / 40 mg prednisolone / 40 mg prednisone.

Subjects who have received corticosteroids for 5 consecutive days or more up to the day of screening.

Pregnant woman.

Participation in another therapeutic trial study that collide.

Lack of informed consent.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
All-cause hospital mortality.

All-cause hospital mortality.

Secondary Outcome Measures
NameTimeMethod
Proportions with viral RNA detection over time.

Proportions with viral RNA detection over time.

Number of ventilator free-days (VFDs) at Day 28 (defined as days alive and free from mechanical ventilation at day 28 after intubation. For subjects ventilated >=28 days and for subjects who die, VFD is 0.

Number of ventilator free-days (VFDs) at Day 28 (defined as days alive and free from mechanical ventilation at day 28 after intubation. For subjects ventilated >=28 days and for subjects who die, VFD is 0.

Mortality at ICU and at Day 28.

Mortality at ICU and at Day 28.

Duration (in days) on mechanical ventilation.

Duration (in days) on mechanical ventilation.

Length of stay (in days) in the hospital for survivors.

Length of stay (in days) in the hospital for survivors.

Time (in days) from treatment initiation to death.

Time (in days) from treatment initiation to death.

Trial Locations

Locations (11)

Hospital Clinico San Carlos

🇪🇸

Madrid, Spain

Fundacio Assistencial De Mutua De Terrassa Fpc

🇪🇸

Terrassa, Spain

Hospital Clinic De Barcelona

🇪🇸

Barcelona, Spain

Hospital Virgen De La Luz

🇪🇸

Cuenca, Spain

Hospital Universitario Regional De Malaga

🇪🇸

Malaga, Spain

Hospital Clinico Universitario De Valencia

🇪🇸

Valencia, Spain

Clinica Universidad De Navarra

🇪🇸

Pamplona, Spain

Hospital Universitario Ramon Y Cajal

🇪🇸

Madrid, Spain

Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Hospital Universitario Rio Hortega

🇪🇸

Valladolid, Spain

Scroll for more (1 remaining)
Hospital Clinico San Carlos
🇪🇸Madrid, Spain
María Paloma González Arenas
Site contact
670576645
pgarenas@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.